Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Testen van lage dosis gemeenschappelijke chemotherapie (liposomale doxorubicine) in combinatie met een antikankermedicijn, peposertib, bij gevorderd sarcoom

13 november 2026 bijgewerkt door: National Cancer Institute (NCI)

Een fase 1-studie van peposertib (M3814) en laaggedoseerde liposomale doxorubicine (Doxil®) bij patiënten met gemetastaseerd leiomyosarcoom en andere wekedelensarcomen

This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sarcoma that has spread from where it first started, to other places in the body (metastatic), or cannot be removed by surgery (unresectable) and for which no known cure is available (advanced). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Liposomal doxorubicin is a form of the anticancer drug doxorubicin that is contained inside very tiny, fat-like particles. Liposomal doxorubicin may have fewer side effects and work better than other forms of the drug. Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also enhance the activity of chemo- and radiotherapy. There is some pre-clinical evidence in animal models that combining peposertib with liposomal doxorubicin can shrink or stabilize certain types of cancer for longer than either drug alone, but it is not known if this will happen in people. Combination therapy with liposomal doxorubicin and peposertib may be effective in treating patients with advanced sarcoma.

Studie Overzicht

Gedetailleerde beschrijving

PRIMARY OBJECTIVES:

I. To evaluate the safety and tolerability of peposertib in combination with low-dose pegylated liposomal doxorubicin hydrochloride (liposomal doxorubicin) as evaluated by the dose-limiting toxicity (DLT) rate at each tested dose level.

II. To determine the recommended phase 2 dose (RP2D) of liposomal doxorubicin and peposertib combination and determine the maximal tolerated dose (MTD) if identified.

SECONDARY OBJECTIVE:

I. To assess the pharmacokinetics of peposertib and liposomal doxorubicin used in combination with each other.

CORRELATIVE OBJECTIVES:

I. To test the hypothesis that soft tissue sarcomas (STS) with homologous recombination deficiency (HRD) like leiomyosarcomas (LMS) will be more susceptible to DNA-protein kinase inhibitor (PKi) in combination with low-dose liposomal doxorubicin.

II. To test the hypothesis that gammaH2AX and pNBS1 can be used as pharmacodynamic biomarkers of response to DNA-PKi in combination with low-dose liposomal doxorubicin.

III. To test the hypothesis that disease activity correlates with circulating tumor DNA levels in the plasma.

OUTLINE: This is a dose-escalation study of peposertib and liposomal doxorubicin.

Patients receive peposertib orally (PO) twice daily (BID) on days 1-28 of each cycle and liposomal doxorubicin intravenously (IV) on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression, unacceptable toxicity or withdrawal of consent. Patients undergo blood sample collection and computed tomography (CT) or magnetic resonance imaging (MRI) throughout the trial. Patients also undergo tissue biopsy and echocardiography (ECHO) or multigated acquisition scan (MUGA) during screening and on the trial.

Patients are followed for 30 days after removal from study or until death, whichever occurs first.

Studietype

Ingrijpend

Inschrijving (Geschat)

30

Fase

  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • California
      • Los Angeles, California, Verenigde Staten, 90033
        • Werving
        • USC / Norris Comprehensive Cancer Center
        • Hoofdonderzoeker:
          • Mark Agulnik
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 323-865-0451
      • Los Angeles, California, Verenigde Staten, 90033
        • Werving
        • Los Angeles General Medical Center
        • Hoofdonderzoeker:
          • Mark Agulnik
        • Contact:
    • Colorado
      • Aurora, Colorado, Verenigde Staten, 80045
        • Werving
        • UCHealth University of Colorado Hospital
        • Hoofdonderzoeker:
          • Breelyn A. Wilky
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 720-848-0650
    • Florida
      • Miami, Florida, Verenigde Staten, 33136
        • Werving
        • University of Miami Miller School of Medicine-Sylvester Cancer Center
        • Hoofdonderzoeker:
          • Emily E. Jonczak
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 305-243-2647
    • Illinois
      • Chicago, Illinois, Verenigde Staten, 60637
        • Actief, niet wervend
        • University of Chicago Comprehensive Cancer Center
      • New Lenox, Illinois, Verenigde Staten, 60451
        • Actief, niet wervend
        • UC Comprehensive Cancer Center at Silver Cross
      • Orland Park, Illinois, Verenigde Staten, 60462
        • Actief, niet wervend
        • University of Chicago Medicine-Orland Park
    • Maryland
      • Baltimore, Maryland, Verenigde Staten, 21287
        • Werving
        • Johns Hopkins University/Sidney Kimmel Cancer Center
        • Contact:
        • Hoofdonderzoeker:
          • H. Catherine Wilbur
      • Bethesda, Maryland, Verenigde Staten, 20892
        • Werving
        • National Cancer Institute Developmental Therapeutics Clinic
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 800-411-1222
        • Hoofdonderzoeker:
          • A P. Chen
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02215
        • Werving
        • Dana-Farber Cancer Institute
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 877-442-3324
        • Hoofdonderzoeker:
          • Candace L. Haddox
    • Michigan
      • Ann Arbor, Michigan, Verenigde Staten, 48109
        • Geschorst
        • University of Michigan Rogel Cancer Center
    • Missouri
      • St Louis, Missouri, Verenigde Staten, 63110
        • Werving
        • Washington University School of Medicine
        • Hoofdonderzoeker:
          • Mia C. Weiss
        • Contact:
      • St Louis, Missouri, Verenigde Staten, 63129
        • Werving
        • Siteman Cancer Center-South County
        • Hoofdonderzoeker:
          • Mia C. Weiss
        • Contact:
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Verenigde Staten, 15232
        • Werving
        • UPMC Hillman Cancer Center
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 412-647-8073
        • Hoofdonderzoeker:
          • Melissa A. Burgess
    • Texas
      • Houston, Texas, Verenigde Staten, 77030
        • Werving
        • UT MD Anderson Cancer Center
        • Contact:
        • Hoofdonderzoeker:
          • Michael S. Nakazawa
    • Virginia
      • Charlottesville, Virginia, Verenigde Staten, 22908

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Patients must have histologically confirmed sarcoma that is metastatic or unresectable and for which there is no known curative treatment

  • Patients must have histologic diagnosis of leiomyosarcoma (LMS) or selected soft tissue sarcomas (myxofibrosarcoma [MFS], undifferentiated pleomorphic sarcoma [UPS], synovial sarcoma, or dedifferentiated liposarcoma [DDLPS]). Pathology review and confirmation of diagnosis will occur at the site enrolling the patient on this study. If the pathology has previously been reviewed by another site participating in the study, the diagnosis does not need to be re-reviewed at the enrolling site

  • Patients must have evaluable disease that is amenable to biopsy

  • Patients must have been treated with at least 1 prior line of therapy. Prior anthracycline use is permitted as long as the cumulative dose prior to enrollment does not exceed 360 mg/m^2

  • Age >= 18 years. Because no dosing or adverse event data are currently available on the use of peposertib (M3814) in combination with liposomal doxorubicin in patients < 18 years of age, children are excluded from this study

  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)

  • Absolute neutrophil count >= 1,500/mcL

  • Platelets >= 100,000/mcL

  • Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)

  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional ULN

  • Hemoglobin >= 8 g/dL

  • Glomerular filtration rate (GFR) >= 51 mL/min/1.73 m^2 (per institutional estimate based on creatinine level)

  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial

  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated

  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load

  • Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression and clinical symptoms are stable while off steroid support

  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial

  • Patients with known history of clinically significant cardiac disease, or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better

  • Female patients of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required

    • Female patients of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 3 months after the last dose of peposertib (M3814) and 6 months after the last dose of liposomal doxorubicin
  • Male patients of reproductive potential must agree to avoid impregnating a partner while receiving study drug and for 3 months after the last dose of peposertib (M3814) and 6 months after the last dose of liposomal doxorubicin by complying with adequate methods of contraception

    • Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient
  • Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally-authorized representative (LAR) and/or family member available will also be eligible

Exclusion Criteria:

  • Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia

  • Prior palliative radiotherapy within 14 days of cycle 1 day 1 and prior definitive radiotherapy within 42 days of cycle 1 day 1. Adverse effects of radiation therapy must resolve to baseline prior to cycle 1 day 1

  • Patients who are receiving any other investigational agents

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to peposertib (M3814) or other agents used in study

  • Patients who cannot discontinue concomitant medications or herbal supplements that are strong inhibitors or strong inducers of cytochrome P450 (CYP) isoenzymes CYP3A4/5, CYP2C9, and CYP2C19. Participants who cannot discontinue substrates with a narrow therapeutic index that are metabolized by CYP1A2, CYP2B6, CYP2C8, and CYP3A4/5 are ineligible. Patients may confer with the study doctor to determine if alternative medications can be used. The following categories of medications and herbal supplements must be discontinued for at least the specified period of time before the patient can be treated:

    • Strong inducers of CYP3A4/5 and CYP2C19: >= 3 weeks prior to study treatment
    • Strong inhibitors of CYP3A4/5 and CYP2C19: >= 1 week prior to study treatment
    • Substrates of CYP3A4/5 with a narrow therapeutic index: >= 1 day prior to study treatment
    • Strong inhibitors of CYP2C9: >= 1 week prior to study treatment
  • Patients who cannot discontinue concomitant proton-pump inhibitors (PPIs). Patients may confer with the study doctor to determine if such medications can be discontinued. These must be discontinued >= 5 days prior to study treatment. Patients do not need to discontinue calcium carbonate

  • Patients with left ventricular ejection fraction (LVEF) measurement below the institutional lower limit of normal (LLN) are excluded

  • Patients with uncontrolled intercurrent illness

  • Patients who cannot swallow tablets whole

  • Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are not eligible

  • Pregnant women are excluded from this study because peposertib (M3814) is an adenosine triphosphate (ATP)-competitive inhibitor of DNA-protein kinase catalytic subunit (PKcs) with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with peposertib (M3814), breastfeeding should be discontinued if the mother is treated with peposertib (M3814). These potential risks may also apply to other agents used in this study

  • Patients may not have received prior treatment with a DNA-protein kinase (PK) inhibitor

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Treatment (peposertib, liposomal doxorubicin)

Patients receive peposertib PO BID on days 1-28 of each cycle and liposomal doxorubicin IV on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression, unacceptable toxicity or withdrawal of consent. Patients undergo blood sample collection and CT or MRI throughout the trial. Patients also undergo tissue biopsy and ECHO or MUGA during screening and on the trial.

Undergo blood sample collection

Andere namen:
  • Biologische monsterverzameling
  • Biospecimen verzameld
  • Specimenverzameling
  • Monsterverzameling

Undergo MRI

Andere namen:
  • MRI
  • Magnetische resonantie
  • Magnetic Resonance Imaging-scan
  • Medische beeldvorming, magnetische resonantie / nucleaire magnetische resonantie
  • DHR
  • MR-beeldvorming
  • MRI scan
  • NMR-beeldvorming
  • NMRI
  • Nucleaire magnetische resonantie beeldvorming
  • Magnetische resonantiebeeldvorming (MRI)
  • sMRI
  • Magnetische resonantiebeeldvorming (procedure)
  • MRI's
  • Structurele MRI

Undergo ECHO

Andere namen:
  • Echocardiografie
  • EG

Undergo MUGA

Andere namen:
  • Blood Pool-scan
  • Equilibrium radionuclide angiografie
  • Gated Blood Pool-beeldvorming
  • MUGA
  • Radionuclide ventriculografie
  • RNVG
  • SYMA scannen
  • Gesynchroniseerde Multigated Acquisitie Scannen
  • MUGA-scan
  • Multi-Gated Acquisitie Scan
  • Radionuclide ventriculogram scan
  • Gated Heart Pool-scan
  • RNV-scan

Undergo CT scan

Andere namen:
  • CT
  • KAT
  • CT-scan
  • Axiale computertomografie
  • Computergestuurde axiale tomografie
  • Computergestuurde tomografie
  • tomografie
  • Geautomatiseerde axiale tomografie (procedure)
  • Computertomografie (CT)-scan
  • Diagnostische kattencan
  • Diagnostisch CAT -scanservice type

Given IV

Andere namen:
  • ATI-0918
  • Caelyx
  • Doxil
  • Doxilen
  • Doxorubicine HCl Liposoom
  • Duomeisu
  • Ontruimen
  • LipoDox
  • Liposomale adriamycine
  • Liposomaal ingekapselde doxorubicine
  • Gepegyleerd Doxorubicine HCl Liposoom
  • S-liposomale doxorubicine
  • Stealth liposomale doxorubicine
  • TLC-D-99
  • Dox-SL
  • Doxorubicine HCl Liposomaal
  • Doxorubicine hydrochloride liposoom
  • Lipodox 50
  • Liposomaal doxorubicinehydrochloride
  • Gepegyleerde liposomale doxorubicine
  • Doxorubicine Liposomaal

Undergo tissue biopsy

Andere namen:
  • Bx
  • BIOSY_TYPE
  • Biopsie

Given PO

Andere namen:
  • MSC2490484A
  • 3-pyridazinemethanol, alfa-(2-chloor-4-fluor-5-(7-(4-morfolinyl)-4-chinazolinyl)fenyl)-6-methoxy-, (alphaS)-
  • M 3814
  • M-3814
  • M3814
  • MSC 2490484A
  • MSC-2490484A
  • Nedisertib

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Dose limiting toxicity (DLT) rate
Tijdsspanne: Up to 28 days

The number and type of DLT seen at each dose level will be provided. The adverse events (AEs) will also be summarized by AE type and the maximum grade of the AE experienced by the patient for each dose level. DLT will be used to determine the recommended phase 2 dose of study drugs.

Up to 28 days

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Incidence of adverse events
Tijdsspanne: Up to 30 days after the end of study treatment

AEs will be assessed using Common Terminology Criteria for Adverse Events version 5.

Up to 30 days after the end of study treatment
Objective response rate
Tijdsspanne: Up to 28 days

Assessed with Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1.

Up to 28 days
Progression free survival
Tijdsspanne: From study enrollment until disease progression (determined by RECIST v1.1) or death due to any cause, whichever occurs first

The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. Patients who are alive at the time of analysis without a documented disease progression will be censored at the time of their last tumor evaluation.

From study enrollment until disease progression (determined by RECIST v1.1) or death due to any cause, whichever occurs first
Homologous recombination deficiency (HRD) status
Tijdsspanne: Up to 1 year

Will be defined by HRD score and mutational signature analysis.

Up to 1 year
Deoxyribonucleic acid damage repair activity
Tijdsspanne: Up to 1 year

Will be defined by gammaH2AX and NBS1 S343 phosphorylation based on the National Clinical Laboratory Network DDR3 assay.

Up to 1 year

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Candace L Haddox, Dana-Farber - Harvard Cancer Center LAO

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

6 februari 2024

Primaire voltooiing (Geschat)

3 mei 2027

Studie voltooiing (Geschat)

3 mei 2027

Studieregistratiedata

Eerst ingediend

2 februari 2023

Eerst ingediend dat voldeed aan de QC-criteria

2 februari 2023

Eerst geplaatst (Werkelijk)

3 februari 2023

Updates van studierecords

Laatste update geplaatst (Werkelijk)

16 november 2026

Laatste update ingediend die voldeed aan QC-criteria

13 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren